NCT06186908 Evaluation of Salivary Gal-7, Gal-10 and MMP-9 Levels of Individuals With Different Periodontal Diseases
| NCT ID | NCT06186908 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Izmir Katip Celebi University |
| Condition | Periodontal Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-05-02 |
| Primary Completion | 2025-01-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-05-02 with a primary completion date of 2025-01-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is; detection of Galectin-10, Galectin-7, MMP-9 levels in saliva samples of periodontally healthy, gingivitis and periodontitis patients and the possible correlation between these values and clinical parameters of periodontal diseases. Materials and methods: Samples of saliva were obtained from 60 systemically healthy non-smoker individuals with periodontitis (P, n=20), gingivitis(G, n=20) and healthy periodontium (S, n=20). Full-mouth clinical periodontal measurements including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were also recorded. Enzyme-linked immunosorbent assay (ELISA) was used to determine Galectin-10, Galectin-7 and MMP-9 levels in the biological samples.
Eligibility Criteria
Inclusion Criteria: * Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.) * At least twenty permanent teeth in the mouth * Non-smoker * No medication for continuous use * Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months. * Not in pregnancy or lactation period. * For the periodontitis group that has not received periodontal treatment in the last 6 months * For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss * For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss * For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study. Exclusion Criteria: * Any oral or systemic disease * Regularly using a systemic medication * During pregnancy or lactation * Received periodontal treatment within the last 6 months. * Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months * Smokers are not included in the study
Contact & Investigator
Mehmet Sağlam
STUDY DIRECTOR
Izmir Katip Çelebi University
Frequently Asked Questions
Who can join the NCT06186908 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 60 Years, studying Periodontal Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06186908 currently recruiting?
Yes, NCT06186908 is actively recruiting participants. Contact the research team at ceren2292@gmail.com for enrollment information.
Where is the NCT06186908 trial being conducted?
This trial is being conducted at Izmir, Turkey (Türkiye).
Who is sponsoring the NCT06186908 clinical trial?
NCT06186908 is sponsored by Izmir Katip Celebi University. The principal investigator is Mehmet Sağlam at Izmir Katip Çelebi University. The trial plans to enroll 60 participants.